Invitation to Minesto's Webinar: Interim Management Statement Q1 2025
GOTHENBURG, Sweden, April 28, 2025 /PRNewswire/ -- On April 30, Minesto, leading ocean energy developer, will publish their Interim Management Statement 1 January - 31 March 2025. Dr Martin Edlund, CEO, and Gustav Kvibling, CFO, will present details...
Celltrion to present six abstracts in inflammatory bowel disease (IBD) at 2025 Digestive Disease Week® (DDW)
Six abstracts accepted for presentation includes post hoc analyses and real-world evidence for ZYMFENTRA ® (infliximab-dyyb) Findings reinforce clinical decision-making in long-term management of moderate-to-severe Crohn's disease and ulcerative...
Fibocom Unleashes the Intelligent Power of AIoT in Korea at WIS 2025
SEOUL, South Korea, April 24, 2025 /PRNewswire/ -- Fibocom, a global leading provider of wireless communication modules and AI solutions, showcases its latest innovative AIoT solutions at World IT Show 2025, held at COEX, Seoul. Fibocom demonstrates...
Sun Pharma and Moebius Medical Announce Dual Publications on MM-II's Phase 2b Clinical Trial Results and Mechanism of Action in Osteoarthritis and Cartilage
- Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA models featured in two peer-reviewed articles - - New data on MM-II to be presented this weekend at the OARSI 2025 World Conference on Osteoarthritis - -...
Kelun-Biotech to Present Results of Six Clinical Studies at 2025 ASCO Annual Meeting
CHENGDU, China, April 24, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announced that it will present results from six Kelun-led clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual...
Seven Oral Presentations: Innovent to Present Breakthrough Clinical Data of IBI363（PD-1/IL-2α-bias）and Other Novel Drug Candidates at the 2025 ASCO Annual Meeting
SAN FRANCISCO and SUZHOU,China, April 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of...
Caliway Selected to Present CBL-514 Phase 2 Study Results for Dercum's Disease at World Orphan Drug Congress USA 2025
CBL-514, Caliway's novel small molecule drug, was selected for data presentation at the World Orphan Drug Congress USA 2025, highlighting its promising Phase 2 study results (CBL-0201DD) for Dercum's Disease Treatment. The Phase 2 topline results...
Seegene Announces Development of CURECA™, a Next-Generation Fully Automated PCR Solution Featuring Customizable Pre-treatment Automation
- Seegene to showcase a conceptual video introducing CURECA™ at ESCMID Global 2025 — a full automation system expected to cover the entire PCR workforce, from sample pre-processing to result analysis. - Designed for 24-hour, seven-days-a-week,...
FDA Watch: The Quiet Gold Rush in AI-Powered Medical Devices
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, April 2, 2025 /PRNewswire/ -- Equity Insider News Commentary – Artificial Intelligence (AI) is quickly becoming a major force in healthcare, as use of AI...
Invitation to presentation of EQT AB's Q1 Announcement 2025
STOCKHOLM, April 2, 2025 /PRNewswire/ -- EQT AB's Q1 Announcement 2025 will be published on Wednesday 16 April 2025 at approximately 07:00 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session. The...